BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
Number Citing Articles
1 Gottlieb A, Best J, Canbay A. Implications of Immunotherapy in Hepatobiliary Tumors. Visc Med 2019;35:18-26. [PMID: 31312646 DOI: 10.1159/000496755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jia W, Wang L. Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity. Evid Based Complement Alternat Med 2020;2020:9843486. [PMID: 32595757 DOI: 10.1155/2020/9843486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Balas L, Durand T. Dihydroxylated E,E,Z-docosatrienes. An overview of their synthesis and biological significance. Progress in Lipid Research 2016;61:1-18. [DOI: 10.1016/j.plipres.2015.10.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
4 Llewellyn HP, Arat S, Gao J, Wen J, Xia S, Kalabat D, Oziolor E, Virgen-Slane R, Affolter T, Ji C. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model. J Hepatol 2021:S0168-8278(21)01887-0. [PMID: 34242700 DOI: 10.1016/j.jhep.2021.06.037] [Reference Citation Analysis]
5 Poupiot J, Costa Verdera H, Hardet R, Colella P, Collaud F, Bartolo L, Davoust J, Sanatine P, Mingozzi F, Richard I, Ronzitti G. Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle. Mol Ther Methods Clin Dev 2019;15:83-100. [PMID: 31649958 DOI: 10.1016/j.omtm.2019.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
6 Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, Cui X, Liu X, Huang M, Cui G, Sun R. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol 2021;9:687756. [PMID: 34277630 DOI: 10.3389/fcell.2021.687756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Longerich T, Schirmacher P. Emerging Role of the Pathologist in Precision Medicine for HCC. Dig Dis Sci 2019;64:928-33. [PMID: 30815826 DOI: 10.1007/s10620-019-05548-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brown ZJ, Heinrich B, Greten TF. Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. Methods Protoc 2018;1:E21. [PMID: 31164564 DOI: 10.3390/mps1020021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yu Z, Guo J, Liu Y, Wang M, Liu Z, Gao Y, Huang L. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J Nanobiotechnology 2022;20:9. [PMID: 34983554 DOI: 10.1186/s12951-021-01205-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.Ther Adv Med Oncol. 2019;11:1758835919862692. [PMID: 31384311 DOI: 10.1177/1758835919862692] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
11 Yoon SH, Choi SW, Nam SW, Lee KB, Nam JW. Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. NPJ Precis Oncol 2021;5:27. [PMID: 33772139 DOI: 10.1038/s41698-021-00167-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
13 Liao X, Bu Y, Jia Q. Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. Genes Dis 2020;7:370-9. [PMID: 32884991 DOI: 10.1016/j.gendis.2019.10.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
14 Hwang I, Park I, Yoon SK, Lee JL. Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor. Asia Pac J Clin Oncol 2021. [PMID: 34219393 DOI: 10.1111/ajco.13601] [Reference Citation Analysis]
15 Chen DP, Ning WR, Li XF, Wei Y, Lao XM, Wang JC, Wu Y, Zheng L. Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma. Autophagy 2018;14:1335-46. [PMID: 29940792 DOI: 10.1080/15548627.2018.1474994] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
16 Lou X, Wang JJ, Wei YQ, He YJ, Jiang ZJ, Sun JJ. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures. Med Oncol 2021;38:50. [PMID: 33786682 DOI: 10.1007/s12032-021-01499-6] [Reference Citation Analysis]
17 Zhao Y, Wang J, Liu WN, Fong SY, Shuen TWH, Liu M, Harden S, Tan SY, Cheng JY, Tan WWS, Chan JKY, Chee CE, Lee GH, Toh HC, Lim SG, Wan Y, Chen Q. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model. Hepatology 2021;74:1395-410. [PMID: 33738839 DOI: 10.1002/hep.31812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
18 Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Cordie AA, Hassan EM, Omran DA, Leithy R, Elbaz TM. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. Eur J Gastroenterol Hepatol. 2018;30:39-43. [PMID: 29064851 DOI: 10.1097/meg.0000000000001004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
19 Li L, Xia S, Shi X, Chen X, Shang D. The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Sci Rep 2021;11:10728. [PMID: 34021184 DOI: 10.1038/s41598-021-89747-7] [Reference Citation Analysis]
20 Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
21 Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int. 2018;17:301-309. [PMID: 29861325 DOI: 10.1016/j.hbpd.2018.05.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
22 Lo Re O, Mazza T, Giallongo S, Sanna P, Rappa F, Vinh Luong T, Li Volti G, Drovakova A, Roskams T, Van Haele M, Tsochatzis E, Vinciguerra M. Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activation. Theranostics 2020;10:910-24. [PMID: 31903159 DOI: 10.7150/thno.35045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
23 Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology 2019;157:1383-1397.e11. [PMID: 31344396 DOI: 10.1053/j.gastro.2019.07.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
24 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhou T, Liang X, Wang P, Hu Y, Qi Y, Jin Y, Du Y, Fang C, Tian J. A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. ACS Nano 2020;14:12679-96. [PMID: 32909732 DOI: 10.1021/acsnano.0c01453] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
26 Allaire M, Nault J. Molecular targets for HCC and future treatments. Journal of Hepatology 2017;66:234-5. [DOI: 10.1016/j.jhep.2016.07.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Wang L, Ge X, Zhang Z, Ye Y, Zhou Z, Li M, Yan H, Wu L, Bai Q, Li J, Zhu J, Wang Y. Identification of a Ferroptosis-Related Long Noncoding RNA Prognostic Signature and Its Predictive Ability to Immunotherapy in Hepatocellular Carcinoma. Front Genet 2021;12:682082. [PMID: 34745200 DOI: 10.3389/fgene.2021.682082] [Reference Citation Analysis]
28 Sung PS, Jang JW. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. Int J Mol Sci. 2018;19:3648. [PMID: 30463262 DOI: 10.3390/ijms19113648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
29 Zhang C, Peng L, Zhang Y, Liu Z, Li W, Chen S, Li G. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. Med Oncol 2017;34:101. [PMID: 28432618 DOI: 10.1007/s12032-017-0963-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
30 Akiel M, Guo C, Li X, Rajasekaran D, Mendoza RG, Robertson CL, Jariwala N, Yuan F, Subler MA, Windle J, Garcia DK, Lai Z, Chen HH, Chen Y, Giashuddin S, Fisher PB, Wang XY, Sarkar D. IGFBP7 Deletion Promotes Hepatocellular Carcinoma. Cancer Res 2017;77:4014-25. [PMID: 28619711 DOI: 10.1158/0008-5472.CAN-16-2885] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
31 Lu L, Jiang J, Zhan M, Zhang H, Wang QT, Sun SN, Guo XK, Yin H, Wei Y, Li SY, Liu JO, Li Y, He YW. Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology 2021;73:821-32. [PMID: 32767586 DOI: 10.1002/hep.31502] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
32 Wang Z, He L, Li W, Xu C, Zhang J, Wang D, Dou K, Zhuang R, Jin B, Zhang W, Hao Q, Zhang K, Zhang W, Wang S, Gao Y, Gu J, Shang L, Tan Z, Su H, Zhang Y, Zhang C, Li M. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer 2021;9:e002787. [PMID: 34489334 DOI: 10.1136/jitc-2021-002787] [Reference Citation Analysis]
33 Sukowati CHC, Patti R, Pascut D, Ladju RB, Tarchi P, Zanotta N, Comar M, Tiribelli C, Crocè LS. Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma. Biomed Res Int 2018;2018:6435482. [PMID: 30246025 DOI: 10.1155/2018/6435482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
34 Zhao L, Jin Y, Yang C, Li C. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma. Clin Exp Immunol 2020;201:289-96. [PMID: 32474905 DOI: 10.1111/cei.13470] [Reference Citation Analysis]
35 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, Zhang ZY, Lv JJ, Zhang Z, Chen ZN, Bian H. Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy. Front Cell Dev Biol 2019;7:233. [PMID: 31681766 DOI: 10.3389/fcell.2019.00233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
38 De Keukeleire SJ, Vermassen T, Nezhad ZM, Kerre T, Kruse V, Vlierberghe HV, Vermaelen K, Rottey S. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk? Immunotherapy 2021;13:409-18. [PMID: 33487052 DOI: 10.2217/imt-2020-0273] [Reference Citation Analysis]
39 Wu Y, Lin H, You X, Guo T, Sun T, Xu H, Fu X. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Front Oncol 2022;12:764923. [DOI: 10.3389/fonc.2022.764923] [Reference Citation Analysis]
40 Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y, Zhou J, Fan J, Qiu SJ. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767-776. [PMID: 27002937 DOI: 10.1038/bjc.2016.47] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
41 Simoes Eugénio M, Farooq M, Dion S, Devisme C, Raguenes-Nicol C, Piquet-Pellorce C, Samson M, Dimanche-Boitrel MT, Le Seyec J. Hepatocellular Carcinoma Emergence in Diabetic Mice with Non-Alcoholic Steatohepatitis Depends on Diet and Is Delayed in Liver Exhibiting an Active Immune Response. Cancers (Basel) 2020;12:E1491. [PMID: 32521615 DOI: 10.3390/cancers12061491] [Reference Citation Analysis]
42 Ehling J, Tacke F. Role of chemokine pathways in hepatobiliary cancer. Cancer Lett. 2015; Jun 26. [Epub ahead of print]. [PMID: 26123664 DOI: 10.1016/j.canlet.2015.06.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
43 Yu M, Li Z. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. Front Med 2017;11:509-21. [DOI: 10.1007/s11684-017-0546-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
44 Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals (Basel) 2020;14:28. [PMID: 33396181 DOI: 10.3390/ph14010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
46 Zheng X, Zhou Y, Yi X, Chen C, Wen C, Ye G, Li X, Tang L, Zhang X, Yang F, Liu G, Li Y, Hou J. IL-21 receptor signaling is essential for control of hepatocellular carcinoma growth and immunological memory for tumor challenge. Oncoimmunology 2018;7:e1500673. [PMID: 30524894 DOI: 10.1080/2162402X.2018.1500673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Onco Targets Ther. 2019;12:10335-10342. [PMID: 31819517 DOI: 10.2147/ott.s214870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
48 Gu X, Gao XS, Xiong W, Guo W, Han L, Bai Y, Peng C, Cui M, Xie M. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. Onco Targets Ther 2016;9:4805-13. [PMID: 27536144 DOI: 10.2147/OTT.S110713] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
49 Caraballo Galva LD, Cai L, Shao Y, He Y. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. J Genet Genomics. 2020;47:1-15. [PMID: 32089500 DOI: 10.1016/j.jgg.2020.01.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
50 Shojaie L, Ali M, Iorga A, Dara L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B 2021;11:3727-39. [PMID: 35024302 DOI: 10.1016/j.apsb.2021.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Telatin V, Nicoli F, Frasson C, Menegotto N, Barbaro F, Castelli E, Erne E, Palù G, Caputo A. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment. Front Cell Infect Microbiol 2019;9:190. [PMID: 31259160 DOI: 10.3389/fcimb.2019.00190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
52 Murali M, Kumar AR, Nair B, Pavithran K, Devan AR, Pradeep GK, Nath LR. Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clin Transl Oncol 2021. [PMID: 34595736 DOI: 10.1007/s12094-021-02707-5] [Reference Citation Analysis]
53 Xu G, Feng D, Yao Y, Li P, Sun H, Yang H, Li C, Jiang R, Sun B, Chen Y. Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. Oncogene 2020;39:1429-44. [PMID: 31659256 DOI: 10.1038/s41388-019-1072-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
54 Brown ZJ, Gregory S, Hewitt DB, Iacono S, Choe J, Labiner HE, Pawlik TM. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology 2022;42:101748. [DOI: 10.1016/j.suronc.2022.101748] [Reference Citation Analysis]
55 Kielbassa K, Vegna S, Ramirez C, Akkari L. Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers. Front Immunol 2019;10:2215. [PMID: 31611871 DOI: 10.3389/fimmu.2019.02215] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
56 Shi X, Li Q, Wang Y. Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e23957. [PMID: 33545975 DOI: 10.1097/MD.0000000000023957] [Reference Citation Analysis]
57 Yun J, Yu G, Hu P, Chao Y, Li X, Chen X, Wei Q, Wang J. PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression. Immunol Res. 2020;68:436-444. [PMID: 32975728 DOI: 10.1007/s12026-020-09155-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40. [DOI: 10.1007/s10620-019-05516-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
59 Canavese M, Wijesundara D, Maddern GJ, Grubor-Bauk B, Hauben E. Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis. Clin Transl Immunology 2016;5:e101. [PMID: 27867514 DOI: 10.1038/cti.2016.55] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
60 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
61 Li ZQ, Wang HY, Zeng QL, Yan JY, Hu YS, Li H, Yu ZJ. p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma. Cancer Med 2020;9:711-23. [PMID: 31769216 DOI: 10.1002/cam4.2611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
62 El-Khoueiry A. The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:311-317. [PMID: 28561676 DOI: 10.14694/edbk_175230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
63 Xie QK, Zhao YJ, Pan T, Lyu N, Mu LW, Li SL, Shi MD, Zhang ZF, Zhou PH, Zhao M. Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1181252. [PMID: 27622038 DOI: 10.1080/2162402X.2016.1181252] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Lin YH, Wu MH, Yeh CT, Lin KH. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication. Int J Mol Sci. 2018;19. [PMID: 30477236 DOI: 10.3390/ijms19123742] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
65 Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396. [PMID: 31500650 DOI: 10.1186/s13046-019-1396-4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 25.3] [Reference Citation Analysis]
66 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Liu F, Zeng G, Zhou S, He X, Sun N, Zhu X, Hu A. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma. Bull Cancer 2018;105:493-501. [PMID: 29576222 DOI: 10.1016/j.bulcan.2018.01.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
68 Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Reference Citation Analysis]
69 Heinrich S, Castven D, Galle PR, Marquardt JU. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2495. [PMID: 32899197 DOI: 10.3390/cancers12092495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, Pawlik TM. Liver Tumor Microenvironment. Adv Exp Med Biol 2020;1296:227-41. [PMID: 34185296 DOI: 10.1007/978-3-030-59038-3_14] [Reference Citation Analysis]
71 Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology 2019;156:890-903. [PMID: 30578781 DOI: 10.1053/j.gastro.2018.11.071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
72 Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293 [PMID: 31148900 DOI: 10.3748/wjg.v25.i19.2279] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
73 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
74 Brown ZJ, Heinrich B, Steinberg SM, Yu SJ, Greten TF. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. J Immunother Cancer 2017;5:93. [PMID: 29157287 DOI: 10.1186/s40425-017-0298-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
75 Hildebrand D, Eberle ME, Wölfle SM, Egler F, Sahin D, Sähr A, Bode KA, Heeg K. Hsa-miR-99b/let-7e/miR-125a Cluster Regulates Pathogen Recognition Receptor-Stimulated Suppressive Antigen-Presenting Cells. Front Immunol 2018;9:1224. [PMID: 29967604 DOI: 10.3389/fimmu.2018.01224] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
76 Chen SL, Lu SX, Liu LL, Wang CH, Yang X, Zhang ZY, Zhang HZ, Yun JP. eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol 2018;11:125-31. [PMID: 29248802 DOI: 10.1016/j.tranon.2017.11.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
77 Brown ZJ, Greten TF. Immune Therapies. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 239-53. [DOI: 10.1007/978-3-030-21540-8_12] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Wang J, Ling S, Ni J, Wan Y. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. BMC Cancer 2022;22:638. [PMID: 35681134 DOI: 10.1186/s12885-022-09662-6] [Reference Citation Analysis]
79 Bhatt S, Kanoujia J, Dhar AK, Singh RK, Rajangam J. Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma. CCTR 2021;17:148-58. [DOI: 10.2174/1573394716999200818103724] [Reference Citation Analysis]
80 Foerster F, Hess M, Gerhold-Ay A, Marquardt JU, Becker D, Galle PR, Schuppan D, Binder H, Bockamp E. The immune contexture of hepatocellular carcinoma predicts clinical outcome. Sci Rep 2018;8:5351. [PMID: 29599491 DOI: 10.1038/s41598-018-21937-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
81 Shokoohian B, Negahdari B, Aboulkheyr Es H, Abedi-Valugerdi M, Baghaei K, Agarwal T, Maiti TK, Hassan M, Najimi M, Vosough M. Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. J Cell Mol Med 2021;25:8602-14. [PMID: 34423899 DOI: 10.1111/jcmm.16875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Accolla RS, Ramia E, Tedeschi A, Forlani G. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Front Immunol 2019;10:1806. [PMID: 31417570 DOI: 10.3389/fimmu.2019.01806] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
83 Wu S, Xie Z, Yan L, Liu X, Zhang Y, Wang D, Dong J, Sun H. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma. BMC Immunol 2022;23. [DOI: 10.1186/s12865-022-00502-7] [Reference Citation Analysis]
84 Ramia E, Chiaravalli AM, Bou Nasser Eddine F, Tedeschi A, Sessa F, Accolla RS, Forlani G. CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches. Oncoimmunology 2019;8:1548243. [PMID: 30723578 DOI: 10.1080/2162402X.2018.1548243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
85 Lin Y, Yang X, Liu W, Li B, Yin W, Shi Y, He R. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation. Oncogene 2017;36:3599-608. [DOI: 10.1038/onc.2016.516] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 12.0] [Reference Citation Analysis]
86 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
87 Cammarota A, Zanuso V, D’alessio A, Pressiani T, Personeni N, Rimassa L. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Xu F, Chen J, Huang D. Pan-cancer analysis identifies FAM49B as an immune-related prognostic maker for hepatocellular carcinoma. J Cancer 2022;13:278-89. [PMID: 34976189 DOI: 10.7150/jca.65421] [Reference Citation Analysis]
89 Liu X, Cui H, Niu H, Wang L, Li X, Sun J, Wei Q, Dong J, Liu L, Xian CJ. Hydrocortisone Suppresses Early Paraneoplastic Inflammation And Angiogenesis To Attenuate Early Hepatocellular Carcinoma Progression In Rats. Onco Targets Ther 2019;12:9481-93. [PMID: 31807025 DOI: 10.2147/OTT.S224618] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Wadkin JCR, Patten DA, Kamarajah SK, Shepherd EL, Novitskaya V, Berditchevski F, Adams DH, Weston CJ, Shetty S. CD151 supports VCAM-1-mediated lymphocyte adhesion to liver endothelium and is upregulated in chronic liver disease and hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 2017;313:G138-49. [PMID: 28473332 DOI: 10.1152/ajpgi.00411.2016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
92 Wen L, Xin B, Wu P, Lin CH, Peng C, Wang G, Lee J, Lu LF, Feng GS. An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. Hepatology 2019;69:2518-32. [PMID: 30693544 DOI: 10.1002/hep.30528] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
93 Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol 2017;67:65-71. [PMID: 28192185 DOI: 10.1016/j.jhep.2017.01.033] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]
94 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
95 Li Y, He X, Zhang X, Xu Y, Wu Y, Xu X. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma. Life Sci 2021;265:118799. [PMID: 33220285 DOI: 10.1016/j.lfs.2020.118799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
96 Miao L, Zhang Z, Ren Z, Li Y. Application of Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:699060. [PMID: 34513678 DOI: 10.3389/fonc.2021.699060] [Reference Citation Analysis]
97 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
98 Pascale F, Pelage JP, Wassef M, Ghegediban SH, Saint-Maurice JP, De Baere T, Denys A, Duran R, Deschamps F, Pellerin O, Maeda N, Laurent A, Namur J. Rabbit VX2 Liver Tumor Model: A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics. Front Oncol 2022;12:871829. [PMID: 35619923 DOI: 10.3389/fonc.2022.871829] [Reference Citation Analysis]
99 Eggert T, Greten TF. Tumor regulation of the tissue environment in the liver. Pharmacol Ther 2017;173:47-57. [PMID: 28167218 DOI: 10.1016/j.pharmthera.2017.02.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
100 Shetty S, Lalor PF, Adams DH. Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. 2018;15:555-567. [PMID: 29844586 DOI: 10.1038/s41575-018-0020-y] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 30.3] [Reference Citation Analysis]
101 Affolter T, Llewellyn HP, Bartlett DW, Zong Q, Xia S, Torti V, Ji C. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS One 2019;14:e0217276. [PMID: 31112568 DOI: 10.1371/journal.pone.0217276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
102 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
103 Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13:267-276. [PMID: 27063467 DOI: 10.1038/cmi.2016.3] [Cited by in Crossref: 325] [Cited by in F6Publishing: 312] [Article Influence: 54.2] [Reference Citation Analysis]
104 Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2019;21:702-12. [PMID: 30387047 DOI: 10.1007/s12094-018-1975-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
105 Arvanitakis K, Mitroulis I, Germanidis G. Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers (Basel) 2021;13:2899. [PMID: 34200529 DOI: 10.3390/cancers13122899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Ulahannan SV, Duffy AG. Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we? Hepat Oncol 2016;3:183-5. [PMID: 30191038 DOI: 10.2217/hep-2016-0008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. J Gastrointest Oncol 2018;9:377-89. [PMID: 29755778 DOI: 10.21037/jgo.2018.01.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
109 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Jiang W, Fang W. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Front Immunol 2020;11:1037. [PMID: 32547550 DOI: 10.3389/fimmu.2020.01037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
111 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in Crossref: 296] [Cited by in F6Publishing: 296] [Article Influence: 49.3] [Reference Citation Analysis]
112 Xie W, Wang B, Wang X, Hou D, Su H, Huang H. Nine hub genes related to the prognosis of HBV-positive hepatocellular carcinoma identified by protein interaction analysis. Ann Transl Med 2020;8:478. [PMID: 32395522 DOI: 10.21037/atm.2020.03.94] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
113 Xie QK, Zhao YJ, Pan T, Lyu N, Mu LW, Li SL, Shi MD, Zhang ZF, Zhou PH, Zhao M. Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1181252. [PMID: 27622038 DOI: 10.1080/2162402X.2016.1181252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
114 Kusnick J, Bruneau A, Tacke F, Hammerich L. Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma. Immuno 2022;2:185-217. [DOI: 10.3390/immuno2010014] [Reference Citation Analysis]
115 Kalathil SG, Thanavala Y. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells 2021;10:1332. [PMID: 34071188 DOI: 10.3390/cells10061332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer 2017;87:101-12. [PMID: 29145036 DOI: 10.1016/j.ejca.2017.10.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
117 Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, Zhang XF, Zhang HX, Zhou ZQ, Zeng YX, Xia JC. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016;5:e1176653. [PMID: 27622026 DOI: 10.1080/2162402x.2016.1176653] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
118 Macek Jilkova Z, Kurma K, Decaens T. Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment. Cancers (Basel) 2019;11:E1487. [PMID: 31581753 DOI: 10.3390/cancers11101487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
119 Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX, Tan AT, Kennedy PT, Maini M, Urban S, Bertoletti A. Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. J Virol. 2019;93(4). [PMID: 30518652 DOI: 10.1128/jvi.01457-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
120 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
121 Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
122 Donadon M, Marchesi F, Rimassa L, Torzilli G. Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle. Hepatobiliary Surg Nutr 2020;9:86-8. [PMID: 32142066 DOI: 10.21037/hbsn.2019.10.33] [Reference Citation Analysis]
123 Liu GM, Li XG, Zhang YM. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int 2019;19:22. [PMID: 30718977 DOI: 10.1186/s12935-019-0738-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
124 Wu J, Lu M, Li Y, Shang YK, Wang SJ, Meng Y, Wang Z, Li ZS, Chen H, Chen ZN, Bian H. Regulation of a TGF-β1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells. Oncogene 2016;35:5468-79. [PMID: 27041581 DOI: 10.1038/onc.2016.89] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
125 Chen Z, Li S, Shen M, Lu X, Bao C, Chen D, Ding J, Wang Q, Huang S, Cong W, Han L, He X. The Mutational and Transcriptional Landscapes of Hepatocarcinogenesis in a Rat Model. iScience 2020;23:101690. [PMID: 33163943 DOI: 10.1016/j.isci.2020.101690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease 2019;51:681-8. [DOI: 10.1016/j.dld.2018.09.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
127 Liu X, Ren H, Guo H, Wang W, Zhao N. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clin Exp Immunol 2021;203:219-29. [PMID: 33030251 DOI: 10.1111/cei.13535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
128 Sutherland JJ, Webster YW, Willy JA, Searfoss GH, Goldstein KM, Irizarry AR, Hall DG, Stevens JL. Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity. Pharmacogenomics J 2018;18:377-90. [DOI: 10.1038/tpj.2017.17] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
129 Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS. Precision oncology in liver cancer. Ann Transl Med 2018;6:285. [PMID: 30105235 DOI: 10.21037/atm.2018.06.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
130 Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Cancers (Basel) 2019;11:E1078. [PMID: 31366113 DOI: 10.3390/cancers11081078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
131 Kurma K, Manches O, Chuffart F, Sturm N, Gharzeddine K, Zhang J, Mercey-Ressejac M, Rousseaux S, Millet A, Lerat H, Marche PN, Macek Jilkova Z, Decaens T. DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4981. [PMID: 34638465 DOI: 10.3390/cancers13194981] [Reference Citation Analysis]
132 Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh HC, Lee SY, Chan CY, Goh BKP, Chung A, Chow PKH, Albani S. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 2017;114:E5900-9. [PMID: 28674001 DOI: 10.1073/pnas.1706559114] [Cited by in Crossref: 88] [Cited by in F6Publishing: 90] [Article Influence: 17.6] [Reference Citation Analysis]
133 Zhang J, Li H, Gao D, Zhang B, Zheng M, Lun M, Wei M, Duan R, Guo M, Hua J, Liu Q, Bai J, Liu H, Zheng J, Yao H. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biol Ther. 2018;19:475-483. [PMID: 29400599 DOI: 10.1080/15384047.2018.1433501] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
134 Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019; 25(24): 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 19.7] [Reference Citation Analysis]
135 Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel) 2020;12:E2859. [PMID: 33020428 DOI: 10.3390/cancers12102859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
136 Liepelt A, Tacke F. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016;311:G203-9. [DOI: 10.1152/ajpgi.00193.2016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
137 Zou Y, Zou X, Zheng S, Tang H, Zhang L, Liu P, Xie X. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920940928. [PMID: 32874208 DOI: 10.1177/1758835920940928] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
138 Shang BB, Chen J, Wang ZG, Liu H. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. PeerJ 2021;9:e12315. [PMID: 34754620 DOI: 10.7717/peerj.12315] [Reference Citation Analysis]
139 El-Khoueiry A. The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2017;37:311-7. [PMID: 28561676 DOI: 10.1200/EDBK_175230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
140 Zhang R, Zhang Z, Liu Z, Wei D, Wu X, Bian H, Chen Z. Adoptive cell transfer therapy for hepatocellular carcinoma. Front Med 2019;13:3-11. [DOI: 10.1007/s11684-019-0684-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
141 Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653-667. [PMID: 26493646 DOI: 10.1038/nrc4017] [Cited by in Crossref: 166] [Cited by in F6Publishing: 160] [Article Influence: 27.7] [Reference Citation Analysis]
142 Jensen CE, Loaiza-Bonilla A, Bonilla-Reyes PA. Immune checkpoint inhibitors for hepatocellular carcinoma. Hepat Oncol 2016;3:201-11. [PMID: 30191042 DOI: 10.2217/hep-2016-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
143 Peng Q, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases 2022; 10(13): 3989-4019 [DOI: 10.12998/wjcc.v10.i13.3989] [Reference Citation Analysis]
144 Gao W, Li L, Han X, Liu S, Li C, Yu G, Zhang L, Zhang D, Liu C, Meng E, Hong S, Wang D, Guo P, Shi G. Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer 2021;21:331. [PMID: 33789609 DOI: 10.1186/s12885-021-08052-8] [Reference Citation Analysis]
145 Brown ZJ, Greten TF, Heinrich B. Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. Hepatology 2019;70:1437-42. [PMID: 30927283 DOI: 10.1002/hep.30633] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
146 Liu HZ, Deng W, Li JL, Tang YM, Zhang LT, Cui Y, Liang XQ. Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. Oncotarget 2016;7:77558-64. [PMID: 27813499 DOI: 10.18632/oncotarget.13041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
147 Best J, Schotten C, Theysohn JM, Wetter A, Müller S, Radünz S, Schulze M, Canbay A, Dechêne A, Gerken G. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol 2017;30:23-32. [PMID: 28042235 DOI: 10.20524/aog.2016.0092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
148 Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306-321. [PMID: 28317925 DOI: 10.1038/nri.2017.11] [Cited by in Crossref: 442] [Cited by in F6Publishing: 431] [Article Influence: 88.4] [Reference Citation Analysis]
149 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Wang J, Zhang C, He W, Gou X. Effect of m6A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma. Front Oncol 2020;10:3. [PMID: 32038982 DOI: 10.3389/fonc.2020.00003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
151 Li C, Wu X, Zhang W, Li J, Liu H, Hao M, Wang J, Zhang H, Yang G, Hao M, Sheng S, Sun Y, Long J, Hu X, Zhang H, Hu C, Li L, Zheng J. AEG-1 Promotes Metastasis Through Downstream AKR1C2 and NF1 in Liver Cancer. Oncol Res 2014;22:203-11. [PMID: 26351209 DOI: 10.3727/096504015X14386062091352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
152 Chen W, Tang D, Ou M, Dai Y. Mining Prognostic Biomarkers of Hepatocellular Carcinoma Based on Immune-Associated Genes. DNA Cell Biol 2020;39:499-512. [PMID: 32069130 DOI: 10.1089/dna.2019.5099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
153 Liu G, Wu D, Wen Y, Cang S. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets. Bioengineered 2021;12:5253-65. [PMID: 34424809 DOI: 10.1080/21655979.2021.1962147] [Reference Citation Analysis]
154 Chen W, Bi K, Zhang X, Jiang J, Diao H. In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. J Transl Autoimmun 2020;3:100067. [PMID: 33073226 DOI: 10.1016/j.jtauto.2020.100067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
156 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
157 Rao Q, Zuo B, Lu Z, Gao X, You A, Wu C, Du Z, Yin H. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro. Hepatology 2016;64:456-72. [PMID: 26990897 DOI: 10.1002/hep.28549] [Cited by in Crossref: 131] [Cited by in F6Publishing: 125] [Article Influence: 21.8] [Reference Citation Analysis]
158 Lacombe K. Risk of hepatocellular carcinoma after DAA treatment in cirrhotic HIV-HCV-coinfected patients: where do we stand? AIDS 2018;32:1533-4. [PMID: 29957724 DOI: 10.1097/QAD.0000000000001823] [Reference Citation Analysis]
159 Rezaei R, Baghaei K, Hashemi SM, Zali MR, Ghanbarian H, Amani D. Tumor-Derived Exosomes Enriched by miRNA-124 Promote Anti-tumor Immune Response in CT-26 Tumor-Bearing Mice. Front Med (Lausanne) 2021;8:619939. [PMID: 33987190 DOI: 10.3389/fmed.2021.619939] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Huang CY, Wang Y, Luo GY, Han F, Li YQ, Zhou ZG, Xu GL. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. J Immunother. 2017;40:323-333. [PMID: 29028787 DOI: 10.1097/cji.0000000000000187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
161 Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 16.5] [Reference Citation Analysis]
162 Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, Qi H, Guo H, Yin H. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67:739-748. [PMID: 28549917 DOI: 10.1016/j.jhep.2017.05.019] [Cited by in Crossref: 103] [Cited by in F6Publishing: 112] [Article Influence: 20.6] [Reference Citation Analysis]
163 Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol 2020;72:167-82. [PMID: 31449859 DOI: 10.1016/j.jhep.2019.08.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
164 Li W, Wang H, Ma Z, Zhang J, Ou-Yang W, Qi Y, Liu J. Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma. Front Oncol. 2019;9:1019. [PMID: 31681571 DOI: 10.3389/fonc.2019.01019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
165 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
166 Zhang L, Yang Z, Zhang S, Zhou K, Zhang W, Ling S, Sun R, Tang H, Wen X, Feng X, Song P, Xu X, Xie H, Zheng S. Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation. JIR 2022;Volume 15:217-33. [DOI: 10.2147/jir.s345681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Kalathil SG, Thanavala Y. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. Cancer Immunol Immunother. 2016;65:813-819. [PMID: 26910314 DOI: 10.1007/s00262-016-1810-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
168 Chen W, Zhang X, Bi K, Zhou H, Xu J, Dai Y, Diao H. Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance. Front Oncol 2020;10:554165. [PMID: 33072579 DOI: 10.3389/fonc.2020.554165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
169 Sircana A, Paschetta E, Saba F, Molinaro F, Musso G. Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1745. [PMID: 30970564 DOI: 10.3390/ijms20071745] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
170 Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB, Liu L. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022. [PMID: 35599583 DOI: 10.1002/cam4.4818] [Reference Citation Analysis]
171 Personeni N, Pressiani T, Santoro A, Rimassa L. Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212533. [PMID: 30002715 DOI: 10.7573/dic.212533] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
172 Ihling C, Naughton B, Zhang Y, Rolfe PA, Frick-Krieger E, Terracciano LM, Dussault I. Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Front Med (Lausanne) 2019;6:15. [PMID: 30800658 DOI: 10.3389/fmed.2019.00015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
173 Dhanasekaran R, Venkatesh SK, Torbenson MS, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol 2016;64:736-45. [PMID: 26450813 DOI: 10.1016/j.jhep.2015.09.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
174 Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016;65:663-665. [PMID: 27417216 DOI: 10.1016/j.jhep.2016.07.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 12.5] [Reference Citation Analysis]
175 Sällberg M, Pasetto A. Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation. Front Immunol 2020;11:552. [PMID: 32292409 DOI: 10.3389/fimmu.2020.00552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Al Jarroudi O, Chaabouni H, Ulusakarya A, Almohamad W, Gumus Y, Goldschmidt E, Afqir S, Morère JF. Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience. Clin Case Rep 2021;9:2162-7. [PMID: 33936657 DOI: 10.1002/ccr3.3970] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]